{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yan H"],"funding":["Shanghai Academic/Technology Research Leader","Shanghai Hengrui Pharmaceuticals Co., Ltd"],"pagination":["e087617"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11404262"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(8)"],"pubmed_abstract":["<h4>Introduction</h4>Heart failure with preserved ejection fraction (HFpEF) is a prevalent comorbidity among patients with end-stage kidney disease. Although sodium-glucose cotransporter 2 inhibitors are validated in treating heart failure and ameliorating left ventricular hypertrophy among non-dialysis patients, the effects on dialysis patients are unknown. We previously investigated the pharmacokinetics of henagliflozin in patients undergoing haemodialysis (HD) or peritoneal dialysis (PD) and clarified its safety.<h4>Methods and analysis</h4>This multicentre, randomised, double-blind, placebo-controlled trial is being conducted at three hospitals in Shanghai, China. A target of 108 HD or PD patients with HFpEF are randomly allocated to treatment group (henagliflozin 5 mg/day in addition "],"journal":["BMJ open"],"pubmed_title":["Effect of henagliflozin on left ventricular mass index in dialysis patients with HFpEF (HELD-HF): protocol for a multicentre, randomised, double-blind, placebo-controlled trial."],"pmcid":["PMC11404262"],"funding_grant_id":["22XD1431400"],"pubmed_authors":["Pu J","Liu S","Zhou Y","Jiang M","Wang J","Zhang W","Fang Y","Li Y","Li Z","Fang W","Qi Y","Gu L","Wang W","Pang H","Yan H","Lu R"],"additional_accession":[]},"is_claimable":false,"name":"Effect of henagliflozin on left ventricular mass index in dialysis patients with HFpEF (HELD-HF): protocol for a multicentre, randomised, double-blind, placebo-controlled trial.","description":"<h4>Introduction</h4>Heart failure with preserved ejection fraction (HFpEF) is a prevalent comorbidity among patients with end-stage kidney disease. Although sodium-glucose cotransporter 2 inhibitors are validated in treating heart failure and ameliorating left ventricular hypertrophy among non-dialysis patients, the effects on dialysis patients are unknown. We previously investigated the pharmacokinetics of henagliflozin in patients undergoing haemodialysis (HD) or peritoneal dialysis (PD) and clarified its safety.<h4>Methods and analysis</h4>This multicentre, randomised, double-blind, placebo-controlled trial is being conducted at three hospitals in Shanghai, China. A target of 108 HD or PD patients with HFpEF are randomly allocated to treatment group (henagliflozin 5 mg/day in addition ","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Aug","modification":"2026-06-07T07:42:41.905Z","creation":"2026-06-07T03:12:12.451Z"},"accession":"S-EPMC11404262","cross_references":{"pubmed":["39191464"],"doi":["10.1136/bmjopen-2024-087617"]}}